Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial

Autor: Jihen Boussetta, Julie Coussirou, Corinne Nicolino-Brunet, Elisabeth Castanier, Vincent Couallier, Elvenn A. Loret, Sophie Morange, Christine Caloustian, Charleric Bornet, Olivier Blin, Albert Darque, Josiane Casanova, Elisabeth Jouve, Bertrand Dussol, Erwann Loret, Isabelle Ravaux

Publikováno v: Retrovirology
Retrovirology, BioMed Central, 2016, 13 (1), ⟨10.1186/s12977-016-0251-3⟩
Retrovirology, BioMed Central, 2016, pp.21
Retrovirology, 2016, 13 (1), ⟨10.1186/s12977-016-0251-3⟩

International audience; Background: A Tat Oyi vaccine preparation was administered with informed consent to 48 long-term HIV-1 infected volunteers whose viral loads had been suppressed by antiretroviral therapy (cART). These volunteers were rand-omiz

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac9b7cd66e87b62bfa8702a061b7fe6f
https://hal.archives-ouvertes.fr/hal-02077548